EVH — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-06

• consolidated financial statements presented in “Part I – Item 1. Financial Statements” of this Form 10-Q; our 2025 Form 10-K, including the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; and our current reports on Form 8-…

• We experience pricing pressures in the form of competitive prices in addition to rising costs for certain inflation-sensitive operating expenses such as labor, employee benefits and facility leases. We do not believe these impacts were material to our revenues or net loss for the three and six month…

• various business combinations and asset acquisitions and depreciation of property and equipment, including internal-use software development costs.

• Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements divided by the number of months in the period. Specialty Technology and Services Suite Lives on Platform are calculated by summing monthly member…

• Selling, general and administrative expenses as a % of revenue10.5%16.9%12.3%16.6%

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• On July 4, 2025, the One Big Beautiful Bill Act (the “OBBBA”) was enacted into law. The OBBBA amends U.S. tax law, including provisions related to research and development and interest expense. The OBBBA also makes significant changes to the Medicaid, Medicare and ACA Health Exchanges. Changes inclu…

• We experience pricing pressures in the form of competitive prices in addition to rising costs for certain inflation-sensitive operating expenses such as labor, employee benefits and facility leases. We do not believe these impacts were material to our revenues or net loss for the three months ended …

• Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements, plus members managed by Complex Care in capitation arrangements and divided by the number of months in the period. Specialty Technology and Serv…

• Change in fair value of contingent consideration— (280)280 100.0 %

• Selling, general and administrative expenses as a % of revenue14.7%16.2%

Text added vs the prior filing · source: 10-Q · 2026-08-06

• As of June 30, 2026, there was $117.2 million, $62.5 million and $175.0 million principal balance subject to interest under the Company’s Term Loan Facility, Revolving Facility and Second Lien Term Loan Facility, respectively, all of which are subject to interest rates based on the SOFR. In the case…

• As of June 30, 2026, we had $569.3 million of aggregate principal amount of convertible notes outstanding, which are fixed rate instruments and not subject to fluctuations in interest rates.

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• As of March 31, 2026, there was $117.2 million, $72.5 million and $175.0 million principal balance subject to interest under the Company’s Term Loan Facility, Revolving Facility and Second Lien Term Loan Facility, respectively, all of which are subject to interest rates based on the SOFR.

• In the case of (a) the revolving loan, interest is calculated at either the Adjusted Term SOFR (as defined in the Certificate of Designation) plus 4.00%, or the base rate plus 3.00%, (b) the 2024-A Delayed Draw Term Loan and 2024-B Delayed Draw Term Loan, interest is calculated at either the Adjuste…

• As of March 31, 2026, we had $569.3 million of aggregate principal amount of convertible notes outstanding, which are fixed rate instruments and not subject to fluctuations in interest rates.

Text added vs the prior filing · source: 10-Q · 2026-08-06

• Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how

• well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if…

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated,…

Text added vs the prior filing · source: 10-Q · 2026-08-06

• On May 22, 2026, Seth Blackley, the Company’s Chief Executive Officer and a member of the Company’s Board of Directors, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934 (the “…

• On May 22, 2026, Daniel McCarthy, the Company’s President, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934 (the “McCarthy Plan”). The first possible trade date under the McCa…

Text removed vs the prior filing · source: 10-Q · 2026-05-07

• On May 5, 2026, in order to enhance the retention of certain key officers of the Company, the Compensation Committee of the Board of Directors authorized and approved retention award agreements (each, a “Retention Award Agreement”) with Messrs. Blackley, McCarthy and Weinberg (each, an “Executive”),…

• The foregoing summary is not complete and is qualified in its entirety by reference to the form of Retention Award Agreement, filed herewith as Exhibit 10.1 and incorporated herein by reference.